Benefits of Adding Glucagon-Like Peptide 1 Receptor Agonists to Sodium-Glucose Co-Transporter 2 Inhibitors in Diabetic Patients With Atherosclerotic Disease and Heart Failure-Reference-Cited by-同舟云学术

Benefits of Adding Glucagon-Like Peptide 1 Receptor Agonists to Sodium-Glucose Co-Transporter 2 Inhibitors in Diabetic Patients With Atherosclerotic Disease and Heart Failure

Published:2022-10 Issue: Volume:181 Page:87-93
ISSN:0002-9149
Container-title:The American Journal of Cardiology
language:en
Short-container-title:The American Journal of Cardiology

Author:

Lopez Persio David^ORCID,Bhatia Kirtipal,Bohra Chandrashekar,Mahmood Kiran,Baruch Lawrence,Eng Calvin

Publisher

Elsevier BV

Subject

Education,Cultural Studies

Reference27 articles.

1. American Heart Association Council on Epidemiology and Prevention Statistics Committee and Stroke Statistics Subcommittee. Heart disease and stroke Statistics-2021 update: a report From the American Heart Association;Virani;Circulation,2021

2. Prevalence of atherosclerotic cardiovascular disease, heart failure, and chronic kidney disease in patients with type 2 diabetes mellitus: a primary care research network-based study;Goderis;Exp Clin Endocrinol Diabetes,2022

3. Comparison of the effects of glucagon-like peptide receptor agonists and sodium-glucose cotransporter 2 inhibitors for prevention of major adverse cardiovascular and renal outcomes in type 2 diabetes mellitus;Zelniker;Circulation,2019

4. ESC Scientific Document Group. 2019 ESC guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD;Cosentino;Eur Heart J,2020

5. 2020 Expert consensus decision pathway on novel therapies for cardiovascular risk reduction in patients with type 2 diabetes: a report of the American College of Cardiology solution set oversight committee;Das;J Am Coll Cardiol,2020

Cited by 8 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Effectiveness and safety of the combination of sodium–glucose transport protein 2 inhibitors and glucagon-like peptide-1 receptor agonists in patients with type 2 diabetes mellitus: a systematic review and meta-analysis of observational studies;Cardiovascular Diabetology;2024-03-18

2. GLP-1 receptor agonists-SGLT-2 inhibitors combination therapy and cardiovascular events after acute myocardial infarction: an observational study in patients with type 2 diabetes;Cardiovascular Diabetology;2024-01-06

3. Effects of GLP-1 receptor agonists on mitochondrial function, inflammatory markers and leukocyte-endothelium interactions in type 2 diabetes;Redox Biology;2023-10

4. Incretins and cardiovascular disease: to the heart of type 2 diabetes?;Diabetologia;2023-08-05

5. Treating chronic kidney disease to reduce cardiovascular risk;European Heart Journal Supplements;2023-04-01